Monday - December 23, 2024
Dana-Farber Cancer Institute: PARP Inhibition Shows Long-Term Survival Benefits for Patients With High-Risk, BRCA-Positive Breast Cancer
December 13, 2024
BOSTON, Massachusetts, Dec. 13 (TNSres) -- The Dana-Farber Cancer Institute issued the following news release:

Patients with high-risk, BRCA-positive breast cancer who received olaparib after standard treatment continued to have better survival outcomes than those who received placebo after a median follow-up of 6.1 years, according to the latest results from the phase III OlympiA clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS).

"The Oly . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation
Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products